Executive Summary
India’s life sciences sector is moving into a new phase.
The country has already established substantial capabilities in pharmaceuticals, generic medicines, vaccines, biotechnology services and manufacturing. The opportunity now extends much further into advanced therapeutics, diagnostics, medical technology, digital health, Bio-AI, precision medicine and research commercialisation.
India’s bioeconomy reached approximately ₹16.9 lakh crore in 2025, representing about 4.8% of national GDP and recording approximately 18% year-on-year growth. The ecosystem includes 11,855 biotechnology startups, reflecting the increasing depth of innovation and entrepreneurship around biological sciences. birac.nic.in
The larger shift, however, is structural.
India is gradually moving from:
- Manufacturing → Innovation
- Generics → Differentiated technologies
- Research → Commercialisation
- Standalone healthcare → Connected health ecosystems
- Biology alone → Biology + Data + AI
This transition could define the next decade of Indian life sciences.
Life Sciences Is Becoming a Much Larger Indian Opportunity
The traditional view of Indian life sciences has largely centred around pharmaceuticals.
That definition is now too narrow.
The emerging ecosystem includes:
- Biopharmaceuticals
- Vaccines
- Biologics and biosimilars
- Medical devices
- Molecular diagnostics
- Genomics
- Bioinformatics
- Digital health
- Precision medicine
- Cell and gene therapies
- Computational biology
- Industrial biotechnology
- Biomanufacturing
- Clinical and research services
The 2026 India BioEconomy Report estimates the national bioeconomy at approximately ₹16.9 lakh crore, based on its reported US$195.3 billion value. Manufacturing-oriented BioIndustrial and BioPharma activities account for almost three-quarters of the ecosystem, while services and digital life-sciences activities are expanding quickly. birac.nic.in
India is therefore no longer building only a biotechnology industry.
It is building an increasingly interconnected life-sciences ecosystem.
The Economics of India’s Bioeconomy
A ₹16.9 lakh crore ecosystem
India’s bioeconomy has expanded rapidly over the past five years.
Using approximate INR equivalents based on the exchange-rate relationship used within the 2026 official report:
| Year | Approx. Indian Bioeconomy |
|---|---|
| 2020 | ₹7.45 lakh crore |
| 2021 | ₹9.18 lakh crore |
| 2022 | ₹11.87 lakh crore |
| 2023 | ₹13.09 lakh crore |
| 2024 | ₹14.36 lakh crore |
| 2025 | ₹16.9 lakh crore |
The official report puts 2025 growth at 18%, with a 2020–2025 CAGR of approximately 17.8%. birac.nic.in
More importantly, the bioeconomy’s contribution to India’s GDP increased to around 4.8% in 2025, compared with 4.4% in 2024 and 4.2% in 2023. birac.nic.in
That means life sciences and biotechnology are becoming economically significant beyond their traditional industrial boundaries.
Where the ₹16.9 Lakh Crore Economy Comes From
The Indian bioeconomy is not one market.
It is composed of several large segments.
Based on the 2026 report, approximate INR equivalents are:
| Segment | Approx. Value | Share |
|---|---|---|
| BioIndustrial | ₹7.82 lakh crore | 46% |
| BioPharma | ₹5.59 lakh crore | 33% |
| BioServices | ₹2.25 lakh crore | 13% |
| BioAgri | ₹1.27 lakh crore | 8% |
The scale of BioIndustrial and BioPharma remains substantial, but the growth of BioServices, digital life-sciences platforms, research services and global capability centres is particularly important for India’s next phase.
It suggests an ecosystem moving beyond manufacturing volume toward increasingly knowledge-intensive activity.
Biotechnology Is Moving from Laboratory to Market
Scientific capability alone is not enough
A discovery in a laboratory is not yet a healthcare product.
Between research and commercial adoption sits a long development pathway:
- Discovery
- Proof of concept
- Prototype
- Validation
- Clinical evidence
- Regulatory approval
- Manufacturing
- Market adoption
India has historically been strong at science and manufacturing.
A major opportunity now lies in strengthening the bridge between them.
That bridge is research commercialisation.
Successful life-sciences ecosystems need researchers, hospitals, entrepreneurs, industry, regulators and technology partners to work together.
For India, improving this translation from laboratory research into commercial products could unlock significantly more value from its existing scientific base.
Diagnostics Could Become a Major Indian Growth Layer
India’s enormous population, uneven healthcare access and growing burden of chronic disease create a strong need for earlier, cheaper and more accessible diagnosis.
Potential areas include:
- Molecular diagnostics
- Point-of-care testing
- Genomic diagnostics
- Cancer screening
- Infectious-disease testing
- Biomarker analysis
- Pathology automation
- Imaging intelligence
- AI-assisted diagnostics
- Remote diagnostic technologies
Diagnostics sits at an especially valuable intersection:
Biology + Technology + Data + Clinical Practice
That combination makes diagnostics one of the most attractive areas for innovation within India’s life-sciences ecosystem.
The opportunity is not necessarily another standalone laboratory test.
Increasingly, it may be an integrated diagnostic platform connecting sample collection, analysis, clinical interpretation, data and treatment pathways.
Digital Health Is Becoming National Infrastructure
India’s healthcare digitisation is moving beyond individual applications.
The Ayushman Bharat Digital Mission is creating national infrastructure around health identities, healthcare professionals, facilities, records and interoperable health services.
This creates a foundation for:
- Digital health records
- Telemedicine
- Remote patient monitoring
- Clinical workflows
- Hospital technology
- Digital diagnostics
- Healthcare analytics
- Patient engagement
- AI-enabled clinical support
- Research platforms
The deeper opportunity is interoperability.
When health information can move securely between patients, hospitals, laboratories, clinicians and digital platforms, healthcare can become significantly more connected.
For Indian life-sciences businesses, digital health may increasingly function as infrastructure rather than simply software.
Biology + AI Could Change Research Economics
AI is beginning to intersect with biological science in increasingly meaningful ways.
Potential applications include:
- Drug discovery
- Molecular screening
- Protein modelling
- Genomics
- Pathology
- Medical imaging
- Biomarker identification
- Clinical decision support
- Research automation
- Manufacturing optimisation
The traditional model requires large numbers of physical experiments.
AI can potentially help narrow the search space before laboratory validation.
The emerging model becomes:
Computational discovery → Experimental validation → Clinical evidence → Iteration
India’s strength in both technology talent and biological sciences creates an interesting strategic advantage.
The convergence of these capabilities could become one of the country’s most consequential life-sciences opportunities over the coming decade.
Advanced Therapeutics Could Move India Up the Value Chain
India’s pharmaceutical industry became globally competitive through:
scale + process chemistry + manufacturing + generics
The next frontier is more complex.
It includes:
- Biologics
- Biosimilars
- Cell therapies
- Gene therapies
- Immunotherapies
- Precision therapeutics
- Novel drug-delivery systems
These categories require substantially stronger capabilities in research, intellectual property, clinical validation, specialised manufacturing and regulation.
That complexity also creates higher barriers to entry.
India’s opportunity is therefore not simply to manufacture more healthcare products.
It is to participate further upstream in discovery, intellectual property and differentiated therapeutic development.
Medical Technology Can Become Increasingly Indian
India also has an opportunity to shift from primarily consuming imported medical technologies toward developing more technologies domestically.
Areas of opportunity include:
Diagnostics
Screening and point-of-care technologies.
Monitoring
Continuous and remote patient monitoring.
Medical Devices
Clinical and surgical equipment.
Digital Devices
Connected healthcare technologies.
Assistive Technologies
Products supporting rehabilitation and independent living.
AI-enabled Devices
Systems combining hardware, diagnostics and intelligent software.
The strategic opportunity is particularly significant when Indian innovation addresses Indian healthcare constraints:
affordability
accessibility
scale
clinical workforce limitations
geographic reach
A product designed around these realities can potentially serve not only India but other emerging healthcare markets.
Research Commercialisation Is the Critical Bridge
India already possesses significant research capability.
The challenge is ensuring that valuable science does not remain trapped inside laboratories.
Commercialisation requires several participants:
Research institutions
Generate scientific knowledge.
Clinicians
Identify real healthcare problems.
Entrepreneurs
Transform discoveries into products.
Industry
Enable manufacturing and distribution.
Regulators
Establish safety and evidence requirements.
Technology partners
Build digital and computational capability.
Healthcare providers
Enable adoption.
The strongest life-sciences ecosystems connect these participants early.
That reduces the distance between scientific possibility and practical healthcare application.
Four Areas Imprell Life Sciences Is Watching
01Healthcare Innovation
Solutions addressing real gaps in healthcare access, quality and delivery.
Areas include:
- Preventive health
- Diagnostics
- Monitoring
- Care delivery
- Hospital technology
- Patient engagement
- Digital healthcare
Opportunity
Build solutions around real healthcare problems, rather than technology looking for a use case.
Biotechnology & Life Sciences
Scientific technologies capable of producing new therapies, diagnostics or biological products.
Areas include:
- Molecular biology
- Genomics
- Biologics
- Bioinformatics
- Advanced therapeutics
- Biomanufacturing
Opportunity
Move Indian life sciences further toward innovation-led intellectual property and differentiated products.
Research & Development
India’s research infrastructure itself represents an opportunity.
Potential areas include:
- Translational research
- Clinical research
- Laboratory infrastructure
- Research platforms
- Research data
- Technology transfer
- Commercialisation support
Opportunity
Build stronger bridges between science and market adoption.
Strategic Partnerships
Few life-sciences innovations can be developed by one organisation alone.
The emerging model increasingly connects:
Researchers + Clinicians + Startups + Industry + Technology
Opportunity
Create collaboration models capable of accelerating responsible development and commercialisation.
What Will Determine Commercial Success?
Scientific innovation alone does not guarantee commercial success.
A promising Indian life-sciences opportunity should be evaluated against seven questions.
Scientific relevance
Does the science have a credible foundation?
Clinical relevance
Does it solve an important healthcare problem?
Evidence
Can efficacy and safety be demonstrated?
Regulatory pathway
Is there a viable approval route in India?
Manufacturing
Can the product be produced reliably and economically?
Market
Who will adopt and pay for it?
Scale
Can it move beyond a laboratory or pilot programme?
The intersection of these seven factors determines whether an innovation can become a sustainable life-sciences business.
The ₹26 Lakh Crore Opportunity Ahead
Based on the long-term ambition cited in India’s bioeconomy framework, the sector is targeting the equivalent of roughly ₹26 lakh crore by 2030.
Longer term, a ₹80 lakh crore-plus bioeconomy would place life sciences among India’s largest economic ecosystems.
These figures should not be interpreted merely as a market-size forecast.
They signal a larger structural opportunity.
India can potentially evolve from being predominantly a cost-efficient producer of biological and pharmaceutical products into a country increasingly known for:
scientific discovery
healthcare innovation
intellectual property
advanced manufacturing
digital health
Bio-AI
and globally relevant life-sciences companies.
Imprell Life Sciences Perspective
Imprell Life Sciences is at an early stage.
Our current focus is therefore not to claim operating scale across each of these sectors.
It is to understand where meaningful opportunities are emerging and build relationships across the ecosystem.
Our areas of interest are:
Healthcare Innovation
Biotechnology & Life Sciences
Research & Development
Strategic Partnerships
We are particularly interested in opportunities where three factors intersect:
Meaningful science
Real healthcare need
Sustainable commercial potential
That intersection provides a disciplined starting point for identifying where Imprell Life Sciences can participate over time.
Conclusion
India’s next healthcare opportunity may be built between disciplines.
India has already demonstrated its ability to manufacture medicines, vaccines and biological products at enormous scale.
The next chapter could be different.
It may be defined by the convergence of:
Biology + AI
Diagnostics + Digital Health
Research + Entrepreneurship
Science + Manufacturing
Innovation + Healthcare Delivery
India’s life-sciences ecosystem is therefore becoming more than the sum of its industries.
It is becoming an increasingly connected platform for scientific and healthcare innovation.
And that is where the next generation of opportunity may emerge.
India Research Snapshot
| Indicator | Current / Direction |
|---|---|
| India Bioeconomy, 2025 | ≈ ₹16.9 lakh crore |
| Annual Growth, 2025 | 18% |
| Share of Indian GDP | 4.8% |
| Biotech Startups | 11,855 |
| Approx. 2030 Ambition | ₹26 lakh crore |
| Key Growth Areas | Diagnostics, Bio-AI, Digital Health, Advanced Therapeutics, Biomanufacturing |
The official 2026 report states the 2025 bioeconomy at US$195.3 billion, 18% annual growth and 4.8% of GDP; INR values above are approximate conversions made for an India-facing publication. birac.nic.in
